{
    "clinical_study": {
        "@rank": "120940", 
        "arm_group": {
            "arm_group_label": "Single Arm", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The investigators aim to evaluate the safety of delivering a one-time single fraction of\n      Lattice Extreme Ablative Dose (LEAD) radiotherapy followed one day later by standard-dose,\n      conventionally fractionated concurrent chemotherapy and radiation delivered over 6 weeks in\n      patients with bulky stage III non-small cell lung cancer in the setting of a single-arm\n      phase I clinical trial.  The investigators hypothesize that the addition of a one-time\n      single fraction of LEAD radiation is safe and feasible, and will not result in additional\n      toxicity above that expected with standard-dose concurrent chemotherapy and radiation alone."
        }, 
        "brief_title": "Phase 1 Study Evaluating Safety of LEAD Radiotherapy Plus Chemoradiation in Patients With Bulky Stage III Non-Small Cell Lung Cancer", 
        "condition": [
            "Non-Small Cell Lung Cancer", 
            "NSCLC"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have histologically or cytologically documented stage III non-small\n             cell lung cancer including squamous cell, adenocarcinoma, large cell carcinoma and\n             poorly differentiated non-small cell lung cancer.\n\n          -  Patients must have a minimum of 4 cm of measureable disease in any one continuous\n             dimension as seen on diagnostic CT scan.\n\n          -  Pulmonary function tests with FEV1 >= 1.45 liters/second.\n\n          -  Patients must be 21 years of age or older.  There is no maximum age restriction.\n\n          -  Patients must have a Zubrod performance status of 0 or 1.\n\n          -  Patients must have normal organ and marrow function as defined below:\n\n               -  leukocyte > 3,000/:I\n\n               -  absolute neutrophil count >1,500/:1\n\n               -  platelets >100,000/:1\n\n               -  bilirubin within normal institutional limits\n\n               -  AST(SGOT)/ALT(SGPT) 2.5 X institutional upper limit of normal\n\n               -  Creatinine within normal institutional limits  OR creatinine clearance > 60\n                  mL/min/1.73 m2 for patients with creatinine levels above institutional normal.\n\n          -  Patients must have weight loss \u2264 10% over the past three months.\n\n          -  Women of child-bearing potential and men will be asked to use adequate contraception.\n\n          -  Patients must have the ability to understand and the willingness to sign a written\n             informed consent document.\n\n        Exclusion Criteria:\n\n          -  Patients may not have had prior thoracic radiation at any time, or prior chemotherapy\n             for the study cancer at any time.\n\n          -  Patients may not be receiving any other investigational agents for the study cancer.\n\n          -  Patients may not have evidence of brain metastases on baseline CT scan or MRI.\n\n          -  Patients may not have measurable gross disease in the thorax <4 cm in any one\n             continuous dimension.\n\n          -  Patients may not have a cytologically positive pleural effusion.\n\n          -  Patients may not have a prior invasive malignancy (unless disease-free for at least 3\n             years).\n\n          -  Patients may not have had surgical resection of the present cancer.\n\n          -  Women who are pregnant or breastfeeding will be excluded.\n\n          -  Patients must not have any co-morbidity with life expectancy \u2264 6 months, or any\n             uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements.\n\n          -  Patients must not have severe lung disease defined by a history of severe COPD\n             requiring 3 or more hospitalizations over the past year, or history of interstitial\n             pneumonitis.\n\n          -  Patients must not have any concurrent active malignancy.\n\n          -  Patients must not have evidence of metastatic disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "1", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01797471", 
            "org_study_id": "UMIAMI-20100446"
        }, 
        "intervention": [
            {
                "arm_group_label": "Single Arm", 
                "description": "A single fraction of LEAD RT, dose of 18 Gy will be delivered to subjects on day 1", 
                "intervention_name": "Lattice Extreme Ablative Dose Radiation Therapy", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "LEAD Radiotherapy", 
                    "LEAD Radiation Therapy"
                ]
            }, 
            {
                "arm_group_label": "Single Arm", 
                "description": "Conventionally fractionated radiation therapy will be delivered to subjects beginning on day 2 at 2 Gy per fraction for 30 fractions for a total dose of 60 Gy", 
                "intervention_name": "Conventionally Fractionated Radiation", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Single Arm", 
                "description": "Platinum-based chemotherapy doublet administered beginning day 2 via wither weekly or every 3 week regimen. Platinum-based agent selection is at the discretion of the treating medical oncologist", 
                "intervention_name": "Platinum-based Chemotherapy Doublet", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Non-Small Cell Lung Cancer", 
            "NSCLC", 
            "Lung Cancer"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33136"
                }, 
                "name": "University of Miami Sylvester Comprehensive Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Study for Evaluating the Safety of Lattice Extreme Ablative Dose (LEAD) Radiotherapy Followed by Standard-Dose Chemoradiation for Patients With Bulky Stage III Non-Small Cell Lung Cancer", 
        "overall_official": {
            "affiliation": "University of Miami Sylvester Comprehensive Cancer Center", 
            "last_name": "Jean L Wright, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Toxicity will be graded by CTCAE v 4.0. The two toxicities that will be monitored as primary endpoints are esophagitis and pneumonitis.", 
            "measure": "Number of treatment-related adverse events experienced by participants", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01797471"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression-Free Survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Loco-regional failure is defined as any evidence of disease progression within the primary primary tumor or regional lymph nodes, detected by any method.", 
                "measure": "Number of subject experiencing Loco-regional failure", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Number of subjects achieving complete response or partial response according to CT RECIST Response Criteria", 
                "measure": "Number of subjects achieving CT RECIST Response", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Number of subjects achieving as detected by PET Scan: Complete response (CR) is defined as no residual focal FDG uptake or decrease in average FDG uptake by more than 80% in all tumor manifestations. Partial response is defined as standardized uptake value (SUV) decrease by 0 - 80%.", 
                "measure": "Number of subjects achieving Complete or Partial Response via PET response criteria", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "University of Miami Sylvester Comprehensive Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Miami Sylvester Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}